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of Clin
addressAbstract—The aim of the study described here was to characterize three different liver elastography methods in pri-
mary sclerosing cholangitis (PSC) patients, for the first time exploring 2-D shear wave elastography (2-D-SWE) in PSC
patients and its putative advantages over point shear wave elastography (pSWE). Sixty-six adult PSC patients (51 males,
77%) underwent liver elastography: Transient elastography (TE), pSWE and 2-D-SWEwere applied head-to-head after
B-mode ultrasonography and blood tests. Liver stiffness measurements (LSMs) by pSWE yielded lower values than
those by TE; 2-D-SWE had less steep slope but was overall not significantly different from TE. Correlation between
LSMs by pSWE and TE was excellent (intraclass correlation coefficient = 0.92); correlation for 2-D-SWE with either
pSWE or TE was moderate but improved with exclusion of overweight individuals. LSMs correlated with the Enhanced
Liver Fibrosis test (ELF) across all scanner systems. Our study indicates that LSM by different systems is feasible in
PSC patients and that 2-D-SWE tends to underestimate stiffness compared with TE. (E-mail addresses:
abmjelle@gmail.com, adnj@helse-bergen.no) © 2020 The Author(s). Published by Elsevier Inc. on behalf of World
Federation for Ultrasound inMedicine & Biology. This is an open access article under the CC BY license.
(http://creativecommons.org/licenses/by/4.0/).
Key Words: Elastography, Liver fibrosis, Point shear wave elastography, Primary sclerosing cholangitis, Shear
wave elastography, Transient elastography, Ultrasound.INTRODUCTION
Primary sclerosing cholangitis (PSC) is a progressive fibro-
inflammatory disease affecting primarily the bile ducts,
causing strictures and dilations and progressing over time
through increasing stages of liver fibrosis and eventually
cirrhosis. The natural history of PSC is notoriously unpre-
dictable, with population-based studies reporting substan-
tial variation in disease progression (Broome et al. 1996;
Boonstra et al. 2013). Histologic disease stage is associated
with prognosis in PSC but requires invasive biopsies and is
flawed by sampling error and inter-observer variation.
Liver elastography has gained a significant role as a
method for non-invasive evaluation of liver fibrosis in
chronic liver diseases, enabling quantification of liver stiff-
ness as a proxy for fibrosis with a high diagnostic accuracyddress correspondence to: Anders Batman Mjelle, Department
ical Medicine, University of Bergen, Bergen, Norway.E-mail
es: abmjelle@gmail.com, adnj@helse-bergen.no
1854compared with liver biopsy, which is considered the refer-
ence standard (Sandrin et al. 2003; Corpechot et al. 2006;
Friedrich-Rust et al. 2008). Transient elastography (TE)
has exhibited excellent ability to stratify between milder
and severe stages of fibrosis in PSC compared with liver
biopsy, clinical scoring systems and serologic markers and
liver stiffness by TE was associated with clinical outcome
in two independent studies (Corpechot et al. 2014; Ehlken
et al. 2016a, 2016b). However, intermittent cholestasis
caused by (dominant) strictures is common in PSC and has
been reported to affect liver stiffness measurement (LSM)
levels, thus constituting an important confounder (Millonig
et al. 2008).
Liver elastography encompasses several techni-
cally different methods all based on the measurement
of shear wave velocity, such as TE, point shear wave
elastography (pSWE) and 2-D shear wave elastography
(2-D-SWE). pSWE and 2-D-SWE allow simultaneous
B-mode visualization of the liver, which may be
Liver elastography using three scanner systems  A. B. MJELLE et al. 1855particularly useful in PSC to exclude cholestasis as a
confounder. Potentially, 2-D-SWE might have advan-
tages because of visualization of an elastogram before
LSM in PSC, owing to the patchy distribution of fibrosis.
Previous studies in healthy controls of all ages (Mulabe-
cirovic et al. 2018a, 2018b; Mjelle et al. 2019) and in
patients with various liver diseases (Sporea et al. 2014,
2018; Piscaglia et al. 2017; Ferraioli et al. 2019; Iijima et
al. 2019; Lefebvre et al. 2019) have revealed differences
between methods with respect to both LSM levels and
feasibility.
In PSC, data on liver elastography are scarce, par-
ticularly for 2-D-SWE and pSWE and head-to-head
comparisons of methods. Thus, in this study, we aimed
to perform a parallel assessment of three different scan-
ner systems for LSM in PSC patients: TE, pSWE and
2-D-SWE.
METHODS
Patients
The study was performed at Haukeland University
Hospital, Bergen, Norway, in 2017 and 2018. All
patients were part of a well-characterized cohort of non-
transplanted PSC patients. PSC was diagnosed according
to acknowledged criteria. Data collection was performed
prospectively as part of annual study visits consisting of
patient history, clinical examination, blood tests and
ultrasound investigation including liver elastography.
Informed written consent was obtained from all partici-
pants.
B-Mode ultrasound examination
All patients were examined by B-mode ultrasound
scanning of the liver and spleen before liver stiffness
measurements. All examinations were performed by a
single operator (M.V.) using a Philips iU22 (Philips
Healthcare, Andover, MA, USA) scanner with software
Version 6.3.2.2, and a C5-1 convex probe. Scores were
registered for visual signs of liver fibrosis, including
parenchyma heterogeneity, liver capsule regularity, liver
angle, ascites, bile duct variability, sludge or gallbladder
stones. Splenomegaly was defined as a spleen length
12 cm.
Liver stiffness measurements
LSM was measured using a right intercostal
approach in fasting (3 h) patients placed in a supine
position, with the right hand resting under the head. All
measurements were acquired in relaxed mid-ventilation
breath hold with minimal probe pressure. pSWE using
the Philips iU22 (ElastPQ, iU22, Philips Healthcare) was
performed by a single operator (M.V.) using a convex
C5-1 probe, followed head-to-head by examinations byanother single operator (A.B.M.) using 2-D-SWE.GE
(GE S8, GE Healthcare, Milwaukee, WI) with a C1-6
probe, and TE using Fibroscan incorporated into the GE
S8 (GE Healthcare) using an M-probe, or XL-probe if
the machine indicated that the M-probe was not suitable.
2-D-SWE.GE and TE results were given in kilopascals
(kPa), and pSWE results in meters per second (m/s). The
latter values were converted into kilopascals for compar-
ison, using the equation kPa = 3 (m/s)2. Operators were
very experienced (M.V., many years of experience) or
moderately experienced (A.B.M., >300 elastography
measurements with 2-D-SWE.GE and pSWE); both
were certified Fibroscan users. For both pSWE and 2-D-
SWE.GE, a region of interest (for pSWE, a fixed region
of 0.5 £ 1.5 cm, and for 2-D-SWE.GE, a fixed circle
with a diameter of 1 cm) was placed in a homogenous
area 26 cm under the liver capsule, avoiding vessels
and visible bile ducts. Quality criteria were applied
according to the specific manufacturer’s recommenda-
tions: For all systems, a valid measurement required a
success rate 60%, and for 2-D-SWE.GE and TE valid
measurements required an interquartile range divided by
the median (IQR/M) 30%.Enhanced liver fibrosis test
Serum samples were analyzed with the commer-
cially available enhanced liver fibrosis (ELF) test (Sie-
mens Medical Solutions Diagnostics Inc., Tarrytown,
NY, USA), with essays performed with the Siemens
ELF Test kits and an ADVIA Centaur XP analyzer (Sie-
mens Medical Solutions Diagnostics Inc.).Statistical analyses
For all analyses, SPSS Version 25 (IBM, Armonk,
NY, USA) was used. All variables were tested for nor-
mality, and data were presented as the mean (standard
deviation [SD]) or median (range) as appropriate. We
applied Student’s t-test or MannWhitney U-test as
appropriate. Correlations were tested with Pearson’s cor-
relation or Spearman’s rank correlation coefficient as
appropriate. Degree of correlation was defined as poor
(<0.40), moderate (0.400.69), good (0.700.89) or
excellent (0.9). p Values < 0.05 were considered to
indicate statistical significance.Ethical aspects
The protocol was in accordance with the Declara-
tion of Helsinki and approved by the Regional Commit-
tee on Medical and Health Research Ethics of Western
Norway (2012/2214/REK VEST).
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We prospectively recruited and included 66 non-
transplanted PSC patients (51 males, 77.3%) with a
mean (SD) age of 49 y (16.3 y). Median (range) time
since diagnosis was 8 y (037 y). Fifty-eight (78.8%)
patients had inflammatory bowel disease (IBD) and 3
(4.5%) had overlapping features of autoimmune hepati-
tis. Generally, 64.1% of these patients had B-mode find-
ings of liver pathology and/or bile duct pathology, while
25 (39.7%) patients had B-mode findings indicating liver
fibrosis. Liver pathology was defined as coarse paren-
chyma, absence of a smooth liver capsule or blunt liver
angle, while bile duct pathology was mainly segmental
dilations or multifocal strictures or bile duct wall thick-
ening. In 23 patients (35.9%), neither liver pathology nor
bile duct variability was observed. Splenomegaly wasTable 1. Baseline characteristics in patients with PSC under-
going elastography
Number of patients 66
Males 51 (77.3%)
Age, y, mean (SD) 49.0 (16.3)
Age at diagnosis, y, mean (SD) 37.7 (14.9)
Body mass index, kg/m2, mean (SD) 25.7 (4.4)
Body mass index class
<25
2530
30
33 (52.4%)
20 (30.3%)
13 (19.7%)
PSC duration, y, median (range) 8 (037)
IBD (n, %)
Ulcerative colitis
Crohn’s disease
Indeterminate IBD
52 (78.8%)
38 (57.6%)
9 (13.6%)
5 (7.6%)
Feature of autoimmune hepatitis 3 (4.5%)
Decompensated liver disease* 3 (4.5%)
Mayo risk score, median (range) 0.37 (1.89 to 2.94)
APRI score, median (range) 0.47 (0.123.36)
Fib4 score, median (range) 1.29 (0.238.0)
B-Mode ultrasound
Irregular liver capsuley
Subtle irregularity
Moderate-severe irregularity
22 (34.4%)
17 (26.6%)
5 (7.8%)
Coarse liver parenchymay 11 (16.7%)
Blunt liver angle* (missing = 1) 11 (16.7%)
Any liver pathology (missing = 3) 25 (39.7%)
Bile duct variabilityy 31 (47.0%)
Any liver or bile duct pathology 41 (62.1%)
Spleen length, cm, mean (SD) 12.1 (2.2)
Splenomegaly (12 cm) (missing = 3) 33 (52.4%)
Laboratory values, median (range)
Alanine transaminase 47.5 (4657)
Aspartate transaminase 46 (14299)
g-Glutamyl transferase 205 (152389)
Alkaline phosphatase 159 (36863)
Bilirubin 11 (499)
Thrombocytes 232 (68618)
Albumin 45 (3151)
APRI = aspartate transaminase-to-platelet ratio index SD = standard
deviation; IBD = inflammatory bowel disease; PSC = primary scleros-
ing cholangitis.
* Decompensating event before baseline (ascites, variceal bleeding,
encephalopathy or liver synthesis failure).
y Missing = 2.observed in 33 (52.4%) patients. Only a few patients
(n = 3) had significant hyperbilirubinemia (bilirubin >50
mmol/L). Baseline characteristics are summarized in
Table 1.
LSMs by three scanner systems
Feasibility was good to excellent for all systems,
with valid results for TE in 89.4%, for pSWE in 93.9%
and for 2-D-SWE.GE in 71.2%. Median (range) LSM
was 7.1 kPa (3.561.4 kPa) for TE, 4.9 kPa (2.664.9
kPa) for pSWE and 6.4 kPa (4.240.1 kPa) for 2-D-
SWE.GE. Valid results for all three systems were avail-
able for 42 patients (63.6%), with LSM values of 6.4
(3.532.7), 4.7 (2.725.8) and 6.4 (4.534.9) for TE,
pSWE and 2-D-SWE.GE, respectively. Median LSM
was significantly lower by pSWE than by TE (p <
0.001), whereas there were no significant overall differ-
ences between 2-D-SWE.GE and either pSWE or TE.
Intersystem differences were however not linear: 2-D-
SWE.GE was significantly higher than TE for low-aver-
age LSM values, and significantly lower for middle-
range and high-average LSM values (i.e., LSM by 2-D-
SWE.GE exhibited a less steep slope compared with TE;
Fig. 1). Similarly, 2-D-SWE.GE yielded significantly
higher values than pSWE for low to middle-range LSM
values.
LSM values exhibited a good correlation between
systems (r = 0.70, 0.72, 0.65 for pSWE vs. TE, TE vs. 2-
D-SWE.GE and pSWE vs. 2-D-SWE.GE, respectively;
p < 0.001). Correlation improved when patients with
body mass indexes (BMIs) 30 were excluded (r =
0.81, 0.78 and 0.76 for pSWE vs. TE, TE vs. 2-D-SWE.
GE and pSWE vs. 2-D-SWE.GE, respectively). The
intraclass correlation coefficient (ICC) was excellent for
pSWE versus TE (ICC = 0.91, p < 0.001), while moder-
ate for pSWE versus 2-D-SWE.GE and for TE versus 2-
D-SWE.GE (ICC = 0.49, p = 0.013 and 0.43, p = 0.035,
respectively). This discrepancy was largely caused by
BMI. When analyzed for normal-weight individuals
only (n = 31), the ICC values improved to 0.93, 0.92 and
0.81, respectively. By excluding only individuals with a
BMI 30, ICC values were 0.91, 0.6 and 0.43, respec-
tively. In trying to establish a threshold BMI, similar
high ICC values were kept with a cutoff of BMI <28 kg/
m2 for pSWE versus TE (n = 45, ICC = 0.90, p < 0.001)
and 27 kg/m2 for 2-D-SWE.GE versus TE (n = 33; ICC
= 0.81, p < 0.001).
Factors associated with LSM differences between
scanner systems
Difference in LSM (DLSM) between pSWE and TE
was associated with BMI (r = 0.53, p < 0.001) (Fig. 2)
in linear regression, with higher DLSM in the obese.
When patients were classified as either obese (BMI 30)
Fig. 1. Liver stiffness measurements (LSMs) for 2-D shear wave elastography (2-D-SWE.GE) plotted against those for
transient elastography (TE). LSMs by 2-D-SWE.GE were higher than LSMs by TE in patients with a relatively low aver-
age LSM value, while TE values were higher than 2-D-SWE.GE values in patients with a higher average LSM value. A
good correlation was observed (r = 0.716), but two outliers exhibited a major discrepancy. Exclusion of the two outliers
increased r to 0.785. Patients representing these two outliers had quite average body mass indexes (27.5 and 28.1,
respectively) and normal laboratory values. One had B-mode signs of steatosis, and the other had a pathologic liver cap-
sule, but otherwise normal B-mode findings. Both had point shear wave elastography (pSWE) LSM measurements mim-
icking TE values, although one of them were deemed invalid because of a success rate just under 60%.
Liver elastography using three scanner systems  A. B. MJELLE et al. 1857or not obese, the DLSM between pSWE and TE was sig-
nificantly higher in the obese (p = 0.002). Use of the XL
probe for TE in 8 PSC patients was not associated with
increased DLSM between pSWE and TE. DLSM was
not associated with any laboratory value, fibrosis marker
or B-mode finding, nor to LSM levels.
For DLSM for pSWE versus 2-D-SWE.GE or 2-D-
SWE.GE versus TE, there was no difference between
the obese and non-obese (p > 0.3). The DLSM between
pSWE and 2-D-SWE.GE was shown in linear regression
to be affected mainly by the pSWE LSM value (p <
0.001), but otherwise no single factor. DLSM for 2-D-
SWE.GE and TE was significantly associated with LSM
values, mainly by TE (p < 0.001), with serum ALP
(p = 0.009) and GT (p = 0.02) and BMI (p = 0.047).Fig. 2. Scatterplot of difference in liver stiffness values betwee
phy in percent (y-axis) and body mass index (BMI, x-axis), r
with increasing BMI. Looking at the systems separately,Comparison of 2-D-SWE.GE with either TE or
pSWE revealed that there were some outliers with highly
deviant 2-D-SWE.GE LSM values, particularly in the
higher LSM range (Fig. 1). This was further illustrated
with BlandAltman plots (Fig. 3). We did not reveal
any common characteristic explaining this deviance, and
it is thus possible that these were operator dependent.LSMs and suggested prognostic markers (ELF test,
Mayo risk score and spleen length)
LSMs correlated significantly with liver enzymes
and serum-based fibrosis scores (Table 2). In general,
TE and pSWE exhibited higher correlations with all lab-
oratory values compared with 2-D-SWE.GE (Table 2).
LSMs by pSWE, TE and 2-D-SWE.GE all correlated
significantly (r 0.57, 0.59 and 0.40, p  0.009) with then point shear wave elastography and transient elastogra-
= 0.528, p < 0.001. The intersystem difference increases
there was no increasing LSM with increasing BMI.
Fig. 3. BlandAltman plots comparing scanner systems, with average liver stiffness measurements (LSMs) on the x-
axis and intersystem differences on the y-axis, for (a) point shear wave elastography (pSWE) and transient elastography
(TE); (b) TE and 2-D shear wave elastography (2-D-SWE.GE); and (c) pSWE and 2-D-SWE.GE.
Table 2. Correlation between liver stiffness measurements and laboratory values including fibrosis markers*
Laboratory value r (p value)
TE (Fibroscan) pSWE (Philips) 2-D-SWE.GE (GE)
Aspartate transaminase 0.71 (<0.001) 0.60 (<0.001) 0.50 (<0.001)
Alkaline phosphatase 0.69 (<0.001) 0.58 (<0.001) 0.50 (<0.001)
Enhanced liver fibrosis test 0.59 (<0.001) 0.57 (<0.001) 0.40 (0.009)
Mayo risk score 0.57 (<0.001) 0.67 (<0.001) 0.45 (0.001)
Fibrosis 4 (Fib4) score 0.48 (<0.001) 0.59 (<0.001) 0.47 (0.001)
g-Glutamyl transferase 0.59 (<0.001) 0.41 (0.001) 0.39 (0.006)
Bilirubin 0.49 (<0.001) 0.47 (<0.001) 0.35 (0.015)
Alanine transaminase 0.53 (<0.001) 0.36 (0.003) 0.36 (0.01)
Albumin 0.23 (0.081) 0.46 (<0.001) 0.18 (0.23)
IgG4 0.008 (0.955) 0.17 (0.194) 0.173 (0.257)
TE = transient elastography; pSWE = point shear wave elastography; 2-D-SWE.GE = 2-D shear wave elastography.
* Sorted after average r value between all three scanner systems.
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Fig. 4. Correlation between between liver stiffness and scores of fibrosis (enhanced liver fibrosis [ELF] score) or prognosis
(Mayo risk score). For ELF scores, a previously published cutoff value of 11.2 is noted (vertical line), while for transient
elastography (TE), a published cutoff value for cirrhosis of 14.4 is noted (horizontal line). (a) ELF score versus point shear
wave elastography (pSWE). (b) ELF score versus TE. (c) Mayo risk score versus pSWE. (d) Mayo risk score versus TE.
Fig. 5X X. Boxplot revealing a vast difference in liver stiffness measurements between patients with a high Mayo risk score
and a low Mayo risk score (median values: 20.9 kPa vs. 4.5 kPa, p < 0.001).
Liver elastography using three scanner systems  A. B. MJELLE et al. 1859enhanced liver fibrosis (ELF) test, a well-validated
serum biomarker panel based on three direct markers of
fibrosis that has been found to be strongly associated
with clinical outcome in PSC (Vesterhus et al. 2015; de
Vries et al. 2017). The suggested cutoff value for ELF of
11.2 discriminated well between high and low LSMs
(Fig. 7), exhibiting an abrupt rise in LSM values beyond
the cutoff value (Fig. 4a, 4b). LSMs by all methods were
correlated with the Mayo risk score (Table 2). There
seemed to be a cutoff value of 0.5, after which a rapidincrease in LSM values was seen (Fig. 4c, 4d), and
LSMs were elevated in high-risk compared with low-
risk Mayo risk score groups (Fig. 5).
There was no LSM difference between patients
with and without splenomegaly (spleen length 12 cm).
However, at a cutoff of 13 cm, as proposed by a study on
a large healthy patient panel (Chow et al. 2016), patients
with splenomegaly had significantly higher LSM values
by pSWE (4.7 vs. 6.6 kPa, p = 0.019) and TE (6.2 vs. 8.9
kPa, p = 0.034), but not by 2-D-SWE.GE.
Fig. 6. Liver stiffness measurement (LSMs) for all methods, grouped by liver parenchyma on B-mode ultrasound (nor-
mal or coarse liver tissue). LSM values were significantly higher by all scanner systems in patients with coarse liver tis-
sue, although substantially less significant by 2-D-SWE.GE (p = 0.028 vs. p < 0.001 and p < 0.001). TE = transient
elastography; pSWE = point shear wave elastography; 2-D-SWE.GE = 2-D shear wave elastography.
1860 Ultrasound in Medicine & Biology Volume 46, Number 8, 2020LSMs and associations with clinical and B-mode
characteristics in PSC patients
LSMs did not differ between men and women, nor
between obese and non-obese patients, for any scannerTable 3. Comparison of liver stiffness measurements in patients wi
scanning
TE (kPa)
Normal vs. pathologic p Value Normal
Liver parenchyma 6.0 vs. 19.4 <0.001 4.4 vs. 19.
Liver capsule 5.9 vs. 10.1 0.008 4.0 vs. 7.0
Liver angle 6.1 vs. 16.6 0.005 4.6 vs. 12.
Any liver pathology 5.9 vs. 9.2 0.005 4.0 vs. 6.3
Bile duct variability 6.0 vs. 7.1 0.5 4.4 vs. 5.5
Splenomegaly 6.5 vs. 8.0 0.252 4.7 vs. 5.4
TE = transient elastography; pSWE = point shear wave elastography; 2-D-S
* All values are medians.
Fig. 7. Boxplot of liver stiffness measurement (LSM) by point
liver fibrosis (ELF) score of 11.2, discriminating high-risk (11.
higher for patients withsystem. LSMs were significantly higher for all systems
in patients with either coarse liver parenchyma or an
irregular liver capsule (Table 3, Fig. 6) (TE and pSWE:
p < 0.001, 2-D-SWE.GE: p = 0.028).th visible pathology or normal findings on B-mode ultrasound
*
pSWE(kPa) 2-D-SWE.GE (kPa)
vs. pathologic p Value Normal vs. pathologic p Value
2 <0.001 6.3 vs. 8.5 0.028
<0.001 6.2 vs. 7.7 0.009
1 0.019 6.4 vs. 7.2 0.485
0.001 6.2 vs. 7.5 0.055
0.086 6.3 vs. 6.6 0.434
0.442 6.2 vs. 7.2 0.115
WE.GE = 2-D shear wave elastography.
shear wave elastography (pSWE) using a cutoff enhanced
2) from low-risk patients. LSM values were significantly
a high ELF score.
Fig. 8. Receiver operating characteristic curve of liver stiffness measurements by point shear wave elastography
(pSWE) and 2-D shear wave elastography (2-D-SWE.GE) for the diagnosis of advanced fibrosis (F3F4), using pub-
lished cutoff values for transient elastography in a primary sclerosing cholangitis cohort.
Liver elastography using three scanner systems  A. B. MJELLE et al. 1861Discriminative ability of pSWE and 2-D-SWE.GE to
identify significant fibrosis and advanced disease
By applying published cutoff values for fibrosis
staging in PSC using TE (Corpechot et al. 2014), we
identified 50.8% as F0, 10.2% as F1, 1.7% as F2, 23.7%
as F3 and 13.6% as F4. The ability of pSWE as well as
2-D-SWE.GE to discriminate between mild and
advanced (F3F4) disease as defined by TE was good
(area under the receiver operating characteristic curve
[AUROC] = 0.85 for both pSWE and 2-D-SWE.GE),
with optimal cutoff values as decided by Youden’s index
of 4.9 kPa (sensitivity 90.9%, specificity 72.5%) and 7.8
kPa (sensitivity 76.9%, specificity 88.2%) for pSWE and
2-D-SWE.GE, respectively (Fig. 8).DISCUSSION
To the best of our knowledge, this is the first study to
explore the use of 2-D-SWE.GE in PSC with different ultra-
sound elastography scanner systems in a head-to-head fash-
ion in an exclusive PSC cohort. Previous studies have
described the use of either TE (Corpechot et al. 2014;
Ehlken et al. 2016a, 2016b; Krawczyk et al. 2017) or pSWE
(Mjelle et al. 2016; Goertz et al. 2019). Intersystem differen-
ces are known (Mjelle et al. 2016; Dietrich et al. 2017;
Mulabecirovic et al. 2018a, 2018b) and may result from the
different system technologies, but it is unknown how these
are affected by the patchy fibrosis distribution in complex
cholestatic diseases such as PSC, which is histologically dif-
ferent from viral hepatitis and metabolic liver diseases.
We found good to excellent feasibility for all three
elastography systems in PSC patients. Previous studies in
patients with liver diseases are discrepant; some describe a
similar lower feasibility for 2-D-SWE.GE versus TE
(Cassinotto et al. 2014; Staugaard et al. 2016), while othersreport the opposite (Bota et al. 2015; Cassinotto et al.
2015). LSM values in PSC patients were significantly lower
by pSWE than by TE, while measurements with 2-D-SWE.
GE were not different from those by either TE or pSWE.
This is in line with previous results, describing similar inter-
system differences in healthy cohorts (Mulabecirovic et al.
2018a, 2018b; Mjelle et al. 2019) and in various liver dis-
eases (Rizzo et al. 2011; Sporea et al. 2014; Belei et al.
2016; Thiele et al. 2016), as well as phantoms (Mulabecir-
ovic et al. 2016).
We obtained overall lower LSM values by pSWE
than by TE in PSC patients, with a steeper slope for TE
compared with either pSWE or 2-D-SWE.GE (e.g., 2-D-
SWE.GE yielded higher LSM values compared with TE
for low mean LSM values, but lower values in the higher
LSM range; Fig. 1), confirming findings suggested by
previous reports (Cassinotto et al. 2014; Thiele et al.
2016; Mulabecirovic et al. 2018a, 2018b; Mjelle et al.
2019). Such differences between elastography methods
regarding the slope of the LSM curve are important to
acknowledge in clinical follow-up of patients.
We found good correlations for LSM values between
scanner systems (r between 0.65 and 0.72). The ICC for
pSWE versus TE was excellent (0.91). The ICC for 2-D-
SWE.GE versus pSWE or TE was only moderate (0.49 and
0.43, respectively), but improved markedly when excluding
overweight individuals with a BMI >2728 kg/m2, agree-
ing with reports of increased unreliable LSMmeasurements
in patients with a BMI>27.7 kg/m2 (Bota et al. 2014).
Exploring the intersystem difference for LSM values
(DLSM), we found that these correlated with a few select
parameters, which differed between each intersystem com-
parison. DLSM between pSWE and TE was associated
only with BMI (p< 0.001), while DLSM for pSWE and 2-
D-SWE.GE was influenced by the pSWE LSM value (p <
1862 Ultrasound in Medicine & Biology Volume 46, Number 8, 20200.001). DLSM between 2-D-SWE.GE and TE was signifi-
cantly associated with individual LSM values (in particular
TE) (p < 0.001), with serum alkaline phosphatase and
g-glutamyl transferase and ELF values and with BMI. Ear-
lier publications report conflicting results, with some
describing increased failure rate or changing LSM values
with increasing BMI (Guzman-Aroca et al. 2011;
Popescu et al. 2013; Cassinotto et al. 2014; Liao et al.
2015), while some report that BMI exert no effect on LSM
values (Takahashi et al. 2010; Rizzo et al. 2011; Son et al.
2012; Huang et al. 2014; Mulabecirovic et al. 2018a,
2018b). Some of these discrepancies may well be the result
of different study designs, as most studies include no or few
obese (BMI 30 kg/m2) patients, with some studies even
setting the BMI cutoff well into the normal range before
testing for differences, the lowest at 22 kg/m2 (Liao et al.
2015). Taken together, our results suggest that LSM values
in overweight patients with PSC may be subject to
increased uncertainty. Further studies are warranted to tease
out the effects of high BMI on LSM with the various elas-
tography scanner systems.
Limits of agreement analysis revealed a substantial
dispersion in LSM values between all machines, mainly
restricted to average LSM values >10 kPa, as illustrated in
BlandAltman plots (Fig. 3). Our results indicated that 2-
D-SWE.GE gave a more pronounced dispersion in intersys-
tem differences. Patients with the highest DLSM between
TE and pSWE often had invalid results for 2-D-SWE.GE.
This could suggest that the ICC values with 2-D-SWE.GE
measurements were falsely elevated compared with those
with pSWE and TE, as 2-D-SWE.GE had mainly valid
measurements for patients in which LSM was easily mea-
sured and where the different scanner systems agreed.
TE has been reported to correlate well with liver
biopsy in the evaluation of liver fibrosis in PSC patients
(Corpechot et al. 2014). We therefore tested the perfor-
mance of pSWE and 2-D-SWE.GE using TE as a gold
standard, with published cutoff values for different fibro-
sis stages. pSWE and 2-D-SWE.GE both performed well
in the identification of advanced fibrosis (F3F4) with
similar AUROC values of 0.85, with corresponding opti-
mal cutoffs of 4.9 and 7.8 kPa as decided by Youden’s
index.
We found that ELF correlates rather well with
LSMs by pSWE and TE and, more importantly, that
there is a clear linear relationship between the parame-
ters, with an abrupt rise in LSM after the suggested cut-
off for ELF of 11.2. A similar relationship was not
observed for 2-D-SWE.GE, although there was a signifi-
cant correlation.
There was no difference in LSM between those
with and without splenomegaly defined as spleen
length 12 cm, while LSM was elevated in PSC
patients with spleen length 13 cm for pSWE as wellas TE. Previous studies have reported that spleen
length 12 cm is associated with poorer prognosis in
PSC patients (Ehlken et al. 2016a, 2016b). However,
spleen size depends on body length and weight, as
well as sex, and it has been reported that one in four
healthy males has a spleen length 12 cm (Chow et al.
2016). Our findings may indicate that the cutoff values
for spleen length as a prognostic factor might benefit
from body size adjustment or vary between countries,
and perhaps change in spleen size over time may be a
better parameter with respect to disease progression
(Jung et al. 2019).Limitations of the study
The lack of liver biopsies is the main limitation of
this study. Although liver biopsies would have strength-
ened our results, this invasive procedure is not clinically
indicated in PSC, is associated with adverse events and
hence is not acceptable from an ethical perspective. Fur-
thermore, LSMs were not necessarily made at the exact
same spot in the liver with all three scanner systems in
any given patient; in particular, pSWE measurements
were performed by a different operator than TE and 2-D-
SWE.GE measurements. Stricter system recommenda-
tions for TE and 2-D-SWE.GE, requiring IQR/M% 30
for valid results, compared with the Philips iU22 (lack-
ing such recommendations), may have affected results,
in particular the feasibility. Considering the patchy dis-
tribution of PSC, it is possible that LSM measurements
throughout the entire liver would have affected our
results. However, given the results indicating closer
ICCs for TE and pSWE (performed by two observers)
than for TE and 2-D-SWE.GE (performed by a single
observer), we do not believe this biased our results.CONCLUSIONS
We have for the first time described the use of 2-D-
SWE.GE in an exclusive PSC patient cohort, with a
head-to-head comparison using three different elastogra-
phy methods. We found good feasibility and moderate to
excellent correlations for 2-D-SWE.GE, pSWE and TE,
respectively. LSM levels differed between scanner sys-
tems. The ICC was excellent for pSWE versus TE. For
2-D-SWE.GE compared with TE or pSWE, the ICC was
moderate, but improved significantly when overweight
patients were excluded. LSM was correlated with the
ELF test. Our results further suggest that a spleen length
cutoff of 13 cm may be more appropriate as a prognostic
marker in PSC than the recommended 12 cm.
Further research is warranted to clarify the effects
of BMI on LSM for the various elastography scanner
systems and the factors causing diverging LSM values
between scanner systems in PSC patients.
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